If you invested $100 in Viking Therapeutics stock two years ago, here’s how much you would have invested today.

viking cure (VKTX 1.92%) Stock prices are soaring. Two years ago, the stock price was slightly above $2. The stock currently trades around $62. At Friday’s prices, your paltry $100 investment would have grown to over $2,700 in 2022!

Do you still have time to take advantage? totally.

Viking Therapeutics Stock Could Continue to Soar

Viking develops treatments to treat obesity. Two drug candidates, VK2809 and VK2735, are currently undergoing phase 2 clinical trials with promising early results. For example, patients using VK2735 experienced an average weight loss of up to 15% in just 13 weeks.

Viking is achieving timely drug pipeline success. The global market for weight loss drugs is just starting to take off. Goldman Sachs “The chronic weight management market is experiencing an inflection point,” explains one of the company’s analysts. “It has solid growth potential going forward and, in our estimates, could be a top opportunity.” Ultimately, it produces the highest-grossing drug of all time.”

There will be a lot of competition. RocheFor example, ’s CT-388 candidate recently demonstrated an average weight loss of 19% in a small phase 1 trial. But with a market cap of just $7 billion and several more early-stage drug candidates, Viking only needs to capture a small slice of its target market over the next few years to justify its valuation. With available capital of $963 million, there should be no problem bringing the drug to market once Phase 3 clinical trials are successfully completed.

Don’t be surprised to see stocks being extremely volatile here. Viking’s drug pipeline is promising, but commercialization is still years away. And the results of competing drugs can have a big impact on the stock price at any time. However, if you want to invest in the long-term wave of anti-obesity drugs, Viking is still a great choice for patient investors.